Abbott Labs agrees to settle lawsuit over antiretroviral Norvir pricing Abbott Laboratories on Wednesday agreed to pay between $10 million and $27.5 million to settle an antitrust lawsuit filed by HIV/Helps advocates and other medicine companies over an increase in the cost of the business’s antiretroviral medicine Norvir, the AP/International Herald Tribune reports . In December 2003 quadrupled the per-patient wholesale price of Norvir Abbott, which is well known generically as ritonavir. Norvir primarily can be used as a booster for additional protease inhibitors. Abbott exempted Medicaid, Medicare and state AIDS Drug Assistance Applications from the price boost and announced it could expand its patient assistance program.Related StoriesGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningBoston Kids's and Rock Health synergy to accelerate advancement of pediatric wellness technologiesCHOP's Buerger Middle for Advanced Pediatric Treatment celebrates grand opening’Area decontamination technology is a perfect strategic complement to ASP’s existing portfolio of surgical instrument sterilization, high-level hands and disinfection hygiene solutions,’ stated Chuck Austin, Worldwide President of ASP. ‘Healthcare-obtained infections are a growing global concern. ASP is certainly proud to offer patients who need medical center care greater satisfaction, knowing their room gets the added infection protection good thing about this advanced and automated disinfection technology.’ Never gets the need been greater for novel area decontamination systems with healthcare-acquired infection prices rising across the globe.